{
    "Trade/Device Name(s)": [
        "NIOX MINO",
        "NIOX MINO Airway Inflammation Monitor"
    ],
    "Submitter Information": "Aerocrine AB",
    "510(k) Number": "K072816",
    "Predicate Device Reference 510(k) Number(s)": [
        "K021133"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MXA"
    ],
    "Summary Letter Date": "March 3, 2008",
    "Summary Letter Received Date": "February 27, 2008",
    "Submission Date": "February 27, 2008",
    "Regulation Number(s)": [
        "21 CFR 862.3080"
    ],
    "Regulation Name(s)": [
        "Breath Nitric Oxide Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Nitric Oxide"
    ],
    "Specimen Type(s)": [
        "Exhaled breath"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "NIOX MINO Airway Inflammation Monitor"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical detection"
    ],
    "Methodologies": [
        "Quantitative breath analysis"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "Instrument"
    ],
    "Document Summary": "FDA 510(k) summary for NIOX MINO Airway Inflammation Monitor using electrochemical detection to measure fractional exhaled nitric oxide in human breath",
    "Indications for Use Summary": "Quantitative, non-invasive measurement of fractional nitric oxide concentration in expired breath to evaluate response to anti-inflammatory therapy in asthma patients (children 7\u201317 years, adults 18+), as an adjunct to established clinical and laboratory assessments",
    "fda_folder": "Toxicology"
}